Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: A multi-center prospective study

Acute graft versus host disease (aGVHD) remains a major problem after allogeneic hematopoietic stem cell transplantation. Standard frontline therapy for aGVHD involves corticosteroids. However, fewer than half of patients have a lasting complete response. The long-term mortality rate of steroid-refr...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Yamin Tan, Haowen Xiao, Depei Wu, Yi Luo, Jianping Lan, Qifa Liu, Kang Yu, Jimin Shi, Jingsong He, Weiyan Zheng, Xiaoyu Lai, Yuanyuan Zhu, Kaili Du, Yishan Ye, Yanmin Zhao, Gaofeng Zheng, Yongxian Hu, Xiaoyan Han, Yanlong Zheng, Guoqing Wei, Zhen Cai, He Huang
פורמט: Artigo
שפה:Inglês
יצא לאור: Taylor & Francis Group 2017-03-01
סדרה:OncoImmunology
נושאים:
basiliximab
etanercept
hematopoietic stem cell transplantation
steroid-refractory acute gvhd
גישה מקוונת:http://dx.doi.org/10.1080/2162402X.2016.1277307
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים